Novo Integrated Sciences, Inc. (NVOS)
| Market Cap | 61.16K -96.1% |
| Revenue (ttm) | 13.29M +5.7% |
| Net Income | -16.17M |
| EPS | -0.90 |
| Shares Out | 19.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,693 |
| Average Volume | 9,257 |
| Open | 0.0035 |
| Previous Close | 0.0031 |
| Day's Range | 0.0035 - 0.0035 |
| 52-Week Range | 0.0001 - 0.0600 |
| Beta | 4.30 |
| RSI | 48.25 |
| Earnings Date | Dec 18, 2025 |
About Novo Integrated Sciences
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and base... [Read more]
Financial Performance
In fiscal year 2024, Novo Integrated Sciences's revenue was $13.29 million, an increase of 5.75% compared to the previous year's $12.57 million. Losses were -$16.17 million, 22.3% more than in 2023.
Financial StatementsNews
Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results.
Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results.
Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program.
Novo Integrated Sciences files to sell 3.5M shares of common stock for holders
17:17 EDT Novo Integrated Sciences files to sell 3.5M shares of common stock for holders
Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby...
Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company's Board of Directors has approved an increase of ...
Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that its wholly owned Canadian subsidiary, Acenzia Inc. (“Acen...
Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company and RC Consulting Consortium Group LLC, in favor o...
KBRA Assigns AA- to Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024; Affirms Related Ratings
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns a long-term rating of AA- to the Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024. KBRA additionally affirms: The...
Novo Integrated Sciences to conduct review to increase stock repurchase program
As previously reported, the board of directors of Novo Integrated Sciences approved the repurchase of up to $5M of the company’s outstanding common stock from time to time in the…
Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program.
Novo Integrated Sciences announces RWA letter issued by HSBC
Novo Integrated Sciences “announced that as part of a program to monetize a Standby Letter of Credit, the Company has received written confirmation that a Ready, Willing and Able, or…
Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program.
Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results.
Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement.
Novo Integrated Sciences Provides Update on Certain Current Actions and Events
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Provides Update on Certain Current Actions and Events.
Novo Integrated Sciences signs agreement with Futura Surgicare
Novo Integrated Science and Clinical Consultants International a Novo wholly-owned subsidiary, announced the signing of a Consulting Services Agreement, with Futura Surgicare Pvt Ltd, an India-based l...
Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.
Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note.
Novo Integrated Sciences appoints Robert Oliva as new President
Novo Integrated Sciences announces Robert Oliva has been appointed as the company’s new President. Oliva succeeds Christopher David, who remains as the company’s Chief Operating Officer and as a membe...
Novo Integrated Sciences Appoints New President
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Appoints New President.
Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results.
Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences.
Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results.
Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India
BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India.